Currently, the development of highly efficient emission tunable phosphor materials is necessary for improving the lighting quality of UV light based white emitting diodes (WLEDs). Herein, a series of new blue-emitting Ca 7 (Mg, Zn) 2 P 6 O 24 : Eu 2+ (CM/ZP: Eu 2+ ) phosphors were successfully synthesized through a high temperature solid phase reaction process. Interestingly, through constructing Ca 7 (Mg, Zn) 2 P 6 O 24 : Eu 2+ solid solutions based on a complete substitution of Mg 2+ by Zn 2+ , the controllable blue-shift emission from 441 to 418 nm could be realized. This result could be attributed to the selective occupation of different Ca 2+ ions for Eu 2+ ions due to distortion of coordination polyhedron. The corresponding full width at half maximum (FWHM) exhibits a gradual narrowing from 66 to 27 nm after [Zn→Mg] replacement, and the color purity of Eu 2+ emission in Ca 7 Zn 2 P 6 O 24 (CZP) could reach 93.2%. Finally, the thermal quenching resistance of the as-prepared Ca 7 (Mg, Zn) 2 P 6 O 24 : Eu 2+ phosphors show remarkably excellent performance. Moreover, the thermal stabilities working at 150 °C of CMZP: Eu 2+ were gradually improved from 71% for CZP: Eu 2+ to 97% for CMP: Eu 2+ of original photoluminescence intensity. Generally, the cation substation induced selective occupation of Eu 2+ to control FWHM is an efficient design to achieve emission-tunable phosphors, and the developed narrow-band Ca 7 (Mg, Zn) 2 P 6 O 24 : Eu 2+ blue-emitting phosphors could serve as potential blue phosphors for WLEDs application.
Objective The objective of this study was to develop liposomes (LP) containing a curcumin (CU) analog CA7 to enhance its pharmacokinetic profile and anti-cervical cancer (CC) effects.Methods Single-factor and Box-Behnken experiments were conducted to optimize the formulation of CA7-loaded liposomes (CA7-LP). The in vitro release, stability, biocompatibility, and pharmacokinetic of CA7-LP were evaluated. The biological effects of CA7-LP on Hela cells were assessed using MTT assays, colony formation assays, wound healing assays, and flow cytometry. Additionally, the anti-CC efficacy of CA7-LP was tested in mouse models of transplanted tumors.Results The optimal formulation of CA7-LP exhibited a particle size of 92.43 ± 1.52 nm, a polydispersity index of 0.27 ± 0.01, an encapsulation efficiency of 97.79 ± 1.49%, a drug loading of 3.23 ± 0.20%, and a zeta potential of −6.69 ± 0.77 mV. Transmission electron microscopy confirmed that a spherical morphology was exhibited by CA7-LP. The cumulative in vitro release of CA7-LP was found to be 2.84 times greater than that of CA7, and stability at room temperature was maintained for at least 90 d. Furthermore, a significantly higher uptake of CA7-LP by Hela cells was observed compared to curcumin and CA7, leading to enhanced inhibition of cell proliferation, migration and cell cycle, as well as increased apoptosis (p < 0.05). In vivo studies revealed that CA7-LP exhibited superior pharmacokinetic properties compared to CA7 (AUC: 3.58-fold, Cmax: 5.65-fold, t1/2z: 1.2-fold). The anti-CC effects of CA7-LP were found to be comparable to those of Cisplatin injection, with a better safety profile.Conclusion The newly developed CA7-LP is considered a promising candidate for the treatment of CC, demonstrating high potential for clinical application.
危险品化学品经营许可证（带存储）